Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Cancer Cell. 2013 Jun 10;23(6):10.1016/j.ccr.2013.05.003. doi: 10.1016/j.ccr.2013.05.003

Figure 7. The combination of anti-cancer agents plus inhibition of the mitochondrial ATP-synthase overcomes the enrichment of the JARID1Bhigh subpopulation in vitro.

Figure 7

(A) Relative percentage of the J/EGFPhigh subpopulation under combinatorial treatment of WM3734 cells for 72 hr with cisplatin (cis) and oligomycin as determined by flow cytometry (left). Ethanol (EtOH) was used as vehicle control. Immunoblots of the endogenous JARID1B protein expression of WM3734 cells under co-treatment with oligomycin at the indicated time points (right). (B) Cytotoxicity assays of melanoma cell lines after 72 hr of co-treatment with cisplatin (cis) and oligomycin (oligo). (C) Three-dimensional growth/invasion/survival assay of 1205Lu cells treated with vemurafenib (vem) and oligomycin (oligo) for 96 hr. Colony sizes were quantified digitally based on the relative number of pixels. Scale bar represents 500 µm. (D) Soft agar colony forming assay of WM3734 cells after 72-hr pulse treatment with oligomycin (left) and oligomycin plus cisplatin (right). Colonies were counted manually after 5 weeks of growth. Results shown are from one of two independent experiments. Error bars represent SD. See also Figure S5.